Abstract
In this issue of Blood, Sanchorawala and colleagues provide 10-year follow-up of their efforts to treat immunoglobulin light chain (AL) amyloidosis with high-dose melphalan in the 1990s. They report median survival durations approaching 5 years for all patients and exceeding 10 years for those attaining hematologic complete remission.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3490-3491 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 110 |
| Issue number | 10 |
| DOIs | |
| State | Published - Nov 15 2007 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology